<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622502</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-OBS-18-170</org_study_id>
    <nct_id>NCT03622502</nct_id>
  </id_info>
  <brief_title>The Effect of Dexmedetomidine for Emergence Cough</brief_title>
  <official_title>The Effect of Dexmedetomidine on the Remifentanil Concentration for Preventing Cough During Emergence After Propofol Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine or remifentanil are effective in attenuating cough during peri-extubation
      period after general anesthesia. The purpose of this study was to investigate the effect of
      dexmedetomidine on the remifentanil concentration for the cough suppression during anesthetic
      emergence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administration of dexmedetomidine before end of surgery could reduce airway reflexes and
      hemodynamic changes during tracheal extubation. Compared with remifentanil alone,
      administration of dexmedetomidine in combination with remifentanil is effective in relieving
      cough and hemodynamic changes without inhibition of respiration. The purpose of this study
      was to investigate the effect of dexmedetomidine on the remifentanil concentration for the
      cough suppression during anesthetic emergence using the modified up-and-down method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Actual">March 27, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cough</measure>
    <time_frame>from end of surgery to 5 min after tracheal extubation]</time_frame>
    <description>Number of cough or a strong and sudden contraction of the abdomen during periextubation periextubation periods</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Prededex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline was infused over 10 min before end of the surgery</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>0.9% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I or II undergoing endoscopic sinus surgery or septoplasty under
             general anesthesia

        Exclusion Criteria:

          -  predicted difficult airway

          -  body mass index &gt; 35 kg/m2,

          -  recent upper respiratory infection

          -  asthma

          -  current smoker

          -  patients using angiotensin converting enzyme-inhibitors

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Yeop Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University Hospital, Suwon, Gyeongki-do, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeongki-do</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jong Yeop Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>remifentanil</keyword>
  <keyword>extubation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

